Related Experiment Videos
Single-agent carboplatinum for advanced seminoma. A phase II study
H J Schmoll1, A Harstrick, C Bokemeyer
1Department of Hematology/Oncology, Hannover University Medical School, Federal Republic of Germany.
Cancer
|July 1, 1993
Summary
Single-agent carboplatin shows promise for advanced seminoma, achieving high remission rates with mild toxicity. Further trials are needed to confirm survival benefits and identify patients needing cisplatin-based chemotherapy.
Area of Science:
- Oncology
- Medical Chemotherapy
Background:
- Cisplatin-based chemotherapy for advanced seminoma can cause significant side effects.
- Evaluating alternative agents like carboplatin is crucial for improving patient outcomes.
Purpose of the Study:
- To assess the efficacy and safety of single-agent carboplatin in patients with advanced seminoma.
- To determine if carboplatin can achieve remission without compromising future treatment options.
Main Methods:
- Forty-two patients with advanced seminoma received carboplatin (400 mg/m2) every 4 weeks for up to six cycles.
- Treatment response was evaluated based on remission rates, progression, and survival.
- Toxicity, including neurotoxicity and nephrotoxicity, was closely monitored.
Main Results:
- A complete remission (CR) was achieved in 71% of patients, with an additional 19% achieving partial remission (PR).
- Patients with lymph node metastases had higher remission rates (97%) compared to those with visceral metastases (50%).
- Toxicity was mild, with no reported neurotoxicity or nephrotoxicity. Overall survival was 93%.
Conclusions:
- Up-front carboplatin therapy for advanced seminoma appears safe and does not hinder long-term curability.
- Randomized trials are necessary to compare carboplatin's survival impact against cisplatin-based regimens.
- Identifying patient subgroups who benefit most from upfront cisplatin-based chemotherapy requires further investigation.